Top 10 Private Equity Investors: Cancer Therapeutics & Diagnostics
| Rank | Investor Name |
|---|---|
| 1 | Casdin Capital |
| 2 | Ares Management |
| 3 | Bristol-Myers Squibb |
| 4 | Eli Lilly and Company |
| 5 | RA Capital Management |
| 6 | BB Biotech |
| 7 | GSK |
| 8 | Xoma |
| 9 | A&Z Pharmaceuticals |
| 10 | Logos Capital |
Oncology remains the deepest therapeutic category, driven by precision medicine and strategic pharma demand. These are buyers and control investors. This list is most relevant if you are selling the company, recapitalizing, or seeking a majority partner.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Create a free account and get the contacts for the investors above.
Rankings reflect investment activity from January 2025 through July 2026 in US and Canada companies, based on transactions matched to the CapitalDart directory. Seed and Early Stage rank by participation, Later Stage by rounds led, Private Equity by control and buyout activity. Updated periodically.